Use of Local 111In-Capromab Pendetide Scan Results to Predict Outcome After Salvage Radiotherapy for Prostate Cancer
| Autor: | Vladimir Mouraviev, Janice M. Mayes, Bridget F. Koontz, Stephanie H. Chen, Jeffrey L. Johnson, Leon Sun, Mitchell S. Anscher, Judd W. Moul, Thomas J. Polascik, Terence Z. Wong |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty medicine.medical_treatment Salvage therapy Androgen deprivation therapy chemistry.chemical_compound Prostate cancer PSA Failure Prostate medicine Humans Radiology Nuclear Medicine and imaging Radionuclide Imaging Survival rate Aged Retrospective Studies Prostatectomy Salvage Therapy Radiation business.industry Indium Radioisotopes Antibodies Monoclonal Prostatic Neoplasms Prostate-Specific Antigen medicine.disease Surgery Survival Rate medicine.anatomical_structure Pendetide Oncology chemistry Indicators and Reagents Radiology business Follow-Up Studies |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 71:358-361 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2007.10.020 |
| Popis: | Purpose The 111 In-capromab pendetide scan (ProstaScint; Cytogen Corp., Princeton NJ) is approved by the Food and Drug Administration to evaluate increasing prostate-specific antigen (PSA) levels after radical prostatectomy. This study evaluated the role of prostate bed 111 In-capromab pendetide scan findings to predict response to salvage radiotherapy (RT). Methods and Materials Forty patients who had PSA recurrence after radical prostatectomy and a 111 In-capromab pendetide scan immediately before salvage prostate bed RT (median, 66 Gy) were identified from the Duke Prostate Center database. Patients with distant uptake of capromab pendetide or long-term androgen deprivation therapy were excluded. Median follow-up after salvage RT was 2.7 years. Patient demographic, clinical, and pathologic characteristics; PSA values; and 111 In-capromab pendetide scan results were retrospectively analyzed. A PSA failure after salvage RT was defined as PSA level greater than 0.2 ng/ml. Data were combined with other published results in a secondary pooled analysis of 106 patients. Results 111 In-Capromab pendetide findings included 20 patients with negative scan results and 20 with locally positive scan results. Two-year progression-free survival rates were 60% for patients with a negative scan result and 74% for those with a locally positive scan result ( p = 0.49). Combined analysis did not show a difference in outcome based on local 111 In-capromab pendetide scan result. Conclusion For patients without distant signal detected by using 111 In-capromab pendetide scan, patients with locally positive scan findings did not have statistically different progression-free survival than those with a negative scan result, suggesting that salvage RT may be successful in patients with either a locally positive or negative 111 In-capromab pendetide scan result. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|